Subscribe to Newsletter

Oncology

Diagnostics Genetics and epigenetics

Scrutinizing Breast Cancer

| Michael Schubert

The FLEX breast cancer registry intends to collect complete information on 10,000 patients over the course of 10 years

Outside the Lab Profession

Lessons Learned, with Andrew Feinberg

| Andrew Feinberg

A pioneer of epigenetics discusses his career and what he has learned from a fascinating journey through medicine

Diagnostics Biochemistry and molecular biology

Treat or Surveil

| George Vasmatzis and John Cheville

Newly discovered genetic alterations could indicate whether treatment or active surveillance is the best option for low-risk prostate cancer patients

Diagnostics Clinical care

MDLUX2: Drawing a Fuller Picture

| Michael Schubert

Luxembourg’s new molecular diagnostics program aims to establish the value of such analyses as a part of routine cancer care

Inside the Lab Liquid biopsy

Building a Better Biopsy

| Lisa M. Wright

To harness liquid biopsy’s many advantages, it’s vital to ensure appropriate testing – and cfDNA synthetic plasma reference standards can help

Subspecialties Microbiology and immunology

Monitoring the Microbiome

| Luke Turner

Differences in bacterial diversity in the gut could be used to identify patients with Barrett’s esophagus and esophageal cancer

Outside the Lab Screening and monitoring

Steps Forward in Cancer Screening

| Luke Turner

We round up the latest news in pathology and laboratory medicine with these bite-sized stories

Inside the Lab Digital and computational pathology

Watch This Space!

| Anant Madabhushi

The spatial arrangement of immune cells could predict whether aggressive chemotherapy is the best option for patients with early-stage lung cancer

Diagnostics Genetics and epigenetics

Biomarkers on the Brain

| Steve Clifford

A newly discovered chromosome signature offers hope to children with medulloblastoma who may not need intense therapy

Subspecialties Oncology

Kill Command for Cancer

| Luke Turner

Naturally occurring miRNA sequences can be deadly to cancer cells, but can this be ramped up to maximize toxicity?

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register